[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100329364":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Southern California","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Biospecimen Collection",null,"Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.",[13],"Procedure: Biospecimen Collection",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","Undergo collection of saliva",[9],[20],{"name":21,"affiliation":5,"role":22},"Houda Alachkar, Ph.D.","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Christine Duran","CONTACT","323-865-0371","Duran_C@med.usc.edu",[30,50],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Los Angeles General Medical Center","RECRUITING","Los Angeles","California","90033","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-118.24368,34.05223,{"lat":42,"lon":41},[45,49],{"name":46,"role":26,"phone":47,"phoneExt":10,"email":48},"Houda Alachkar, PhD","323-442-2696","alachkar@usc.edu",{"name":46,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":51,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"USC \u002F Norris Comprehensive Cancer Center",{"type":39,"coordinates":53},[41,42],{"lat":42,"lon":41},[56,57],{"name":46,"role":26,"phone":47,"phoneExt":10,"email":48},{"name":46,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[61],{"name":62,"class":63},"National Cancer Institute (NCI)","NIH","100329364","pharmacogenomics-of-asparaginase-induced-hepatotoxicity-100329364",false,"NCT03568266","Pharmacogenomics of Asparaginase Induced Hepatotoxicity","Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL\n* Receiving asparaginase as part of the primary treatment regimen\n* Ability to understand and the willingness to sign a written informed consent\n* For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)\n\nExclusion Criteria:\n\n* Patients who are unable to give informed consent","ALL","18 Years",{"count":74,"type":75},500,"ESTIMATED","OBSERVATIONAL","This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.",[79],"Acute Lymphoblastic Leukemia","2026-05-27",{"date":82,"type":83},"2026-06-01","ACTUAL",{"date":85,"type":83},"2018-05-22",{"date":87,"type":75},"2027-12-31",{"name":5,"class":6},2]